Shuttle Pharmaceuticals Expands Phase 2 Clinical Trial Of Ropidoxuridine For Glioblastoma Treatment To Two Additional Sites, Bringing Total To Four Ready For Patient Enrollment
Portfolio Pulse from Benzinga Newsdesk
Shuttle Pharmaceuticals has expanded its Phase 2 clinical trial of Ropidoxuridine for glioblastoma treatment to two additional sites, totaling four centers ready for patient enrollment. The participating centers are UVA Cancer Center, John Theurer Cancer Center, AHN Cancer Institute, and Miami Cancer Institute.
September 16, 2024 | 1:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Shuttle Pharmaceuticals has expanded its Phase 2 clinical trial for Ropidoxuridine, a treatment for glioblastoma, to four sites, potentially accelerating patient enrollment and trial progress.
The expansion of the clinical trial to additional sites can lead to faster patient enrollment and potentially quicker results, which is positive for Shuttle Pharmaceuticals. This development could enhance investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100